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background:  Implanted Cardiac Defibrillators(ICD’S)are the mainstay of management of sudden death risk in patients with Ischemic (ICMP) and 
Non-Ischemic Cardiomyopathies (NICMP).Fluctuations in left ventricular ejection fraction (LVEF) are common with optimal medical therapy,even 
after device implantation.
methods:  A multicenter,retrospective,data review was performed ,analyzing the incidence of device therapies in patients in whom LVEF had 
improved beyond 40% post device implantation,but initially had a LVEF <35% at device implantation. Mean post-implant LVEF was 47.31%.All 
patients with single,dual and CRT therapy for primary and secondary prophylaxis were included in the analysis.Patients were predominantly in NYHA 
II or III functional class.
results:  A pooled cohort of 396 patient charts were analyzed.There were 271 men(68%),125 women (32%),mean age 66 yrs.There were 218 
patients (55%)with ICMP,178 patients (45%)with NICMP.Only therapies deemed appropriate for VT were included for analysis.There were a total of 
152 therapies,89 (58%) anti tachycardia pacing therapies(ATP) and 63 high energy therapies(42%).All patients were treated with optimal medical 
therapy as appropriate.All therapies were reviewed by experienced clinicians.
conclusion:  A high incidence of appropriate device therapies for ventricular tachyarrhytmias were noted in this study group,despite improvement 
in LVEF,suggesting that ventricular tachyarrhythmias pose a signifiant risk for sudden death in patients with cardiomyopathies and CHF.AICDs offered 
significant protection from sudden death in this group despite improvement in LVEF.This data should be taken into consideration when counseling 
patients for device replacement with improved LVEF.
